Samm Solutions/BTS Research failed good laboratory practice (GLP) rules for nonclinical drug studies, FDA says.
What happened
FDA inspected Samm Solutions, doing business as BTS Research, from June 27 to July 8, 2022, and reviewed two nonclinical laboratory studies of investigational drugs. FDA found that study directors did not accurately record and verify clinical pathology results, did not document unforeseen circumstances or deviations, the quality assurance unit did not ensure final reports matched raw data, and study records were not fully archived. FDA said the company’s two written responses were inadequate because they lacked complete raw data and sufficient corrective-action details.
What FDA found
Study directors did not make sure clinical pathology data were accurately recorded and verified, or document and correct problems that could affect study quality.
21 CFR 58.33(b) and (c)The study director did not authorize or document deviations from standard operating procedures in the raw data, and the final report omitted circumstances that may have affected data quality.
21 CFR 58.81(a); 21 CFR 58.185(a)(9)The quality assurance unit did not ensure that results in the final study reports accurately reflected the raw data.
21 CFR 58.35(b)(6)Study directors did not ensure all raw data, protocols, specimens, and final reports were transferred to the archives at the close of the studies.
21 CFR 58.33(f)
What FDA wants
Within 15 business days of receiving the letter, notify FDA in writing of actions taken to prevent similar violations. FDA also tells the company to address the deficiencies and establish procedures so ongoing and future studies comply.
Who should pay attention
- sponsors relying on BTS Research nonclinical study data
- companies submitting investigational drug applications
- contract research organizations and testing facilities
This is a summary. Read the original letter on fda.gov.